NEPHROS INC (NEPH) - Dilution Analysis
Visualizing historical and potential share dilution over time
Dilution Analysis
Risk Assessment Details
Summary
NEPH currently has 10.6M outstanding shares. with significant dilution risk as 22.5M authorized shares could dilute existing holders by 211.6%. The company has minimally diluted shareholders by 0.99% over the past 2 years.
Share Structure Timeline
Historical Data Points
| Date | Event | Outstanding | Supply |
|---|---|---|---|
| Mar 12, 2026 |
10-K filing | 10.6M shares outstanding |
11M | 22M |
| Nov 06, 2025 |
10-Q filing | 10.6M shares outstanding |
11M | 22M |
| Aug 07, 2025 |
10-Q filing | 10.6M shares outstanding |
11M | 22M |
| May 15, 2025 |
10-Q filing | 10.6M shares outstanding |
11M | 22M |
| Mar 24, 2025 |
10-K filing | 10.6M shares outstanding |
11M | 22M |
| Nov 14, 2024 |
10-Q filing | 10.5M shares outstanding |
11M | 23M |
| Aug 08, 2024 |
10-Q filing | 10.5M shares outstanding |
11M | 23M |
| May 10, 2024 |
S-3 filing: NEPHROS, INC. is filing an S-3 to offer common stock, preferred stock, debt securities, and/or warrants up to $50,000,000. |
11M | 23M |
| May 09, 2024 |
10-Q filing | 10.5M shares outstanding |
11M | 0 |
| Mar 15, 2024 |
10-K filing | 10.4M shares outstanding |
10M | 0 |
| Nov 08, 2023 |
10-Q filing | 10.5M shares outstanding |
10M | 0 |
| Aug 09, 2023 |
10-Q filing | 10.3M shares outstanding |
10M | 44K |
| May 10, 2023 |
10-Q filing | 10.3M shares outstanding |
10M | 44K |
| Mar 23, 2023 |
10-K filing | 10.3M shares outstanding |
10M | 44K |
| Nov 15, 2022 |
10-Q filing | 10.3M shares outstanding |
10M | 38K |
| Aug 15, 2022 |
10-Q filing | 10.3M shares outstanding |
10M | 42K |
| May 05, 2022 |
10-Q filing | 10.2M shares outstanding |
10M | 130K |
| Mar 03, 2022 |
10-K filing | 10.3M shares outstanding |
10M | 83K |
| Nov 04, 2021 |
10-Q filing | 10.2M shares outstanding |
10M | 110K |
| Sep 07, 2021 |
S-3 filing: The selling stockholder is offering 123,981 shares of common stock on a resale basis. |
10M | 120K |
| Aug 05, 2021 |
10-Q filing | 10.2M shares outstanding |
10M | 0 |
| Jul 12, 2021 |
8-K filing: Nephros, Inc. acquired substantially all of the assets of GenArraytion, Inc. for $1.2 million, paid via 123,981 shares of Nephros common stock. ($1.2M proceeds) |
9.9M | 0 |
| May 06, 2021 |
10-Q filing | 9.9M shares outstanding |
9.9M | 0 |
| Mar 01, 2021 |
10-K filing | 9.9M shares outstanding |
9.9M | 0 |
| Nov 05, 2020 |
10-Q filing | 9.0M shares outstanding |
9M | 0 |
| Oct 16, 2020 |
8-K filing: Nephros, Inc. entered into a securities purchase agreement for the issuance and sale of 833,333 shares of its common stock at $6.00 per share in a registered direct offering, with expected net proceeds of approximately $5.0 million for working capital and general corporate purposes; the offering is scheduled to close on or about October 20, 2020. ($5.0M proceeds) |
9M | 0 |
| Aug 05, 2020 |
10-Q filing | 9.0M shares outstanding |
9M | 0 |
| May 06, 2020 |
10-Q filing | 9.0M shares outstanding |
9M | 0 |
| Feb 27, 2020 |
10-K filing | 7.2M shares outstanding |
7.2M | 0 |
| Jan 31, 2020 |
8-K filing: Nephros, Inc. entered into an underwriting agreement for the issuance and sale of 937,500 shares of common stock at $8.00 per share, with expected net proceeds of approximately $7,050,000. ($7.5M proceeds) |
N/A | 0 |